Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 2.92
Day High 3.08
Open:2.99
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
MediPharm Labs Corp has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulation without first receiving a cannabis cultivation license. The focus on cannabis concentrates from current Good Manufacturing Practices and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for derivative products. The company has invested in research-driven team, technology, downstream extraction methodologies and purpose-built facilities to deliver safe and precisely-dosed cannabis products to patients and consumers.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

CannabisNewsBreaks - technical420 Highlights Five "Need-to-Know" Price Target Changes for Cannabis Investors
- CannabisNewsWire - Mon Feb 3, 10:59AM CST
CannabisNewsWire - CMTX
Mon Feb 3, 10:59AM CST
A recent editorial by Anthony Varrell on titled "5 Price Target Changes Cannabis Investors Need To Know" reviews five rating or price target changes by leading broker-dealers that were announced in January. These include changes related to The Scotts Miracle-Gro Company (NYSE: SMG), Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), MediPharm Labs (TSX: LABS) (OTCQX: MEDIF), Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB), and High Tide Inc. (CSE:HITI) (OTCQB:HITIF) (Frankfurt:2LY). "One of the most impactful trends that we have been following in the cannabis sector is related to the activity at the broker-dealer level. When an analyst changes their rating or price target on a company, the market responds, and we find this to be significant," StoneBridge Partners Managing Director Anthony Varrell writes. "2020 has already proven to be a busy year for the cannabis sector and we are barely into February. Today, we want to highlight 5 rating or price target changes that were announced in January by leading broker-dealers."
MediPharm Labs Appoints New Chief Financial Officer
- GlobeNewswire - Mon Nov 4, 5:31AM CST
GlobeNewswire - CMTX
Mon Nov 4, 5:31AM CST
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a global leader in specialized, research-driven cannabis extraction, distillation and purification, is pleased to announce Robert (Bobby) Kwon will join MediPharm Labs as Chief Financial Officer (CFO), effective November 18, 2019. Christopher Hobbs, the Company's current CFO will continue to serve on the Board of MediPharm Labs.
Canada Legalizes Cannabis Edibles, Beverages, Extracts and Other Derivative Products
- PR Newswire - Thu Oct 17, 7:30AM CDT
PR Newswire - CMTX
Thu Oct 17, 7:30AM CDT
On the first anniversary of Canadian cannabis legalization, "Legalization 2.0" or "Cannabis 2.0" will allow popular cannabis derivatives like edibles, infused beverages, and vapes to legally be bought and sold nationwide. Demand for these products is incredibly high, and most analysts believe that cannabis derivatives will allow companies to deliver on ambitious revenue projections for the still-growing pot industry. Because this market is so important, companies that are prepared to capitalize on cannabis-derived consumables--like BevCanna Enterprises Inc. (CSE:BEV) (OTCPK:BVNNF), MediPharm Labs Corp. (TSX:LABS) (OTCQX:MEDIF), Cronos Group (TSX:CRON) (NASDAQ:CRON), Valens GroWorks (TSXV:VGW) (OTCQX:VGWCF), and IAnthus Capital Holdings, Inc. (CSE:IAN) (OTCQX:ITHUF)--are likely to ride the new wave of legalization and become the major industry players of tomorrow.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.47 +23.08% increase
on 02/11/20
Period Open:4.01
Price movement based on the high, low and last over the given period.
4.07 -25.31% decrease
on 01/20/20
-0.97 (-24.19%) decrease
since 01/17/20
3-Month 2.47 +23.08% increase
on 02/11/20
Period Open:4.04
Price movement based on the high, low and last over the given period.
4.45 -31.69% decrease
on 11/21/19
-1.00 (-24.75%) decrease
since 11/19/19
52-Week 2.47 +23.08% increase
on 02/11/20
Period Open:2.97
Price movement based on the high, low and last over the given period.
7.39 -58.86% decrease
on 05/14/19
+0.07 (+2.36%) increase
since 02/19/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies